proteins Inhibitors
1 drugsAbout proteins
Proteins are a crucial class of drug targets, performing diverse functions in normal physiology and disease. Modulating protein activity with drugs can have significant therapeutic effects, impacting various biological processes.
Currently, there is no genetic evidence available linking protein targets to specific diseases. Despite the lack of genetic data, the presence of an approved drug suggests that modulating protein function can provide clinical benefit.
There is one FDA-approved drug, BICNU, targeting proteins, developed by AVET LIFESCIENCES. BICNU, a small molecule, is used in oncology and was first approved in 1977.
Top proteins Drugs
AVET LIFESCIENCES is the only company with an approved drug targeting proteins.
The market is highly concentrated, suggesting high barriers to entry or a lack of investment.
proteins Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets proteins, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could offer a competitive advantage.
proteins Clinical Trials 53 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on proteins. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 20 | 10 | 7 | 3 | 59% |
| Phase 2 | 29 | 11 | 8 | 10 | 58% |
| Phase 3 | 4 | 0 | 3 | 1 | 0% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
proteins Drug Approval Timeline (1977 - 1977)
The first and only drug, BICNU, was approved in 1977.
The lack of recent approvals indicates potential saturation or challenges in developing new protein-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 31 (6 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on proteins. A trial counts if an approved drug acting on proteins is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.